The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.

COCP READ THE FULL COCP RESEARCH REPORT Business Update Fast Track Designation for CDI-988 On April 2, 2026, Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that the U.S. Food and Drug Administration ...

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an ...

CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory ...

Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...

AI predicted that a forgotten breast cancer drug could be repurposed to treat many respiratory and gastrointestinal viruses, ...

Cocrystal stated that the Fast Track designation is aimed at facilitating the development of drugs that treat serious conditions and address unmet medical needs, while also accelerating their review ...

Cork University Hospital has closed its doors to most visitors amid what it's described as an 'unprecedented surge of norovirus,' also known as the winter vomiting bug. The virus can cause a host of ...

NOROVIRUS cases are continuing to soar across Ireland with figures now almost double stats from the last four years. The ...

“Some people will have hay fever from the spring blossom, so will start experiencing symptoms now, although the exact timing ...

A hospital emergency department is "very busy" as staff care for several patients with norovirus, an NHS trust has said.

Visiting is being temporarily restricted until Monday on wards at East Surrey Hospital in Redhill.